Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

To evaluate the antigenic relationship between bat mumps virus (BMV) and the JL5 vaccine strain of mumps virus (MuV(JL5)), we rescued a chimeric virus bearing the F and HN glycoproteins of BMV in the genomic background of MuV(JL5) Cross-reactivity and cross-neutralization between this chimeric rMuV(JL5)-F/HN(BMV) virus and rMuV(JL5) were demonstrated using hyperimmune mouse sera and a curated panel of human sera. All mouse and human sera that were able to neutralize rMuV(JL5) infection had cross-neutralizing activity against rMuV(JL5)-F/HN(BMV) Our data suggests that people who have neutralizing antibodies against MuV might be protected from infection by BMV.

Original publication

DOI

10.1093/infdis/jiw534

Type

Journal article

Journal

J Infect Dis

Publication Date

02/11/2016